• 1
    Man-Son-Hing M, Wells G. Metaanalysis of efficacy of quinine for treatment of nocturnal leg cramps in elderly people. Br Med J 1995; 310: 1317.
  • 2
    Quinine for night cramps. Med Letter Drugs Therapeutics 1986; 28: 110.
  • 3
    Pray S. Nocturnal leg cramps: the dangers of quinine therapy. US Pharm 1992; 17: 1720.62.
  • 4
    Lee FY, Lee SD, Tsai YT, et al. A randomized controlled trial of quinidine in the treatment of cirrhotic patients with muscle cramps. J Hepatol 1991; 12: 240.
  • 5
    Connolly PS, Shirley EA, Wasson JH, Nierenberg DW. Treatment of nocturnal leg cramps. A cross-over trial of quinine vs vitamin E. Arch Int Med 1992; 152: 18771880.
  • 6
    Sidorov J. Quinine sulfate for leg cramps: does it work? J Am Geriat Soc 1993; 41: 498500.
  • 7
    Warbutron A, Royston JP, O'Neill CJA, et al. A quinine a day keeps the leg cramps away? Br J Clin Pharmacol 1987; 23: 459465.
  • 8
    Blagg CR. Acute complications associated with hemodialysis. In Replacement of Renal Function by Dialysis ed. Maher JF. Dornrecht: Kluwer Academic Publishers, 1989.
  • 9
    Sidhom OA, Odeh YK, Krumlovsky FA, et al. Low-dose prazosin in patients with muscle cramps during hemodialysis. Clin Pharmacol Ther 1994; 56: 445451.
  • 10
    Kaji DM, Ackad A, Nottage WG, Stein RM. Prevention of muscle cramps in hemodialysis patients by quinine sulphate. Lancet 1976; ii: 6667.
  • 11
    Roca AO, Jarjourei D, Blend D, et al. Dialysis leg cramps. Efficacy of quinine versus vitamin E. Am Soc Artificial Internal Organs Journal 1992; 38: M481M485.
  • 12
    Wanwimolruk S, Denton JR. Plasma protein binding of quinine; binding to human serum albumin, α1-acid glycoprotein and plasma from patients with malaria. J Pharm Pharmacol 1992; 44: 806811.
  • 13
    Mihaly GW, Ching MS, Klejn MB, Paull J, Smallwood RA. Differences in the binding of quinine and quinidine to plasma proteins. Br J Clin Pharmacol 1987; 24: 769774.
  • 14
    Silamut K, Molunto P, Ho M, White NJ. α1 -acid glycoprotein (orosomucoid) and plasma protein binding of quinine in falciparum malaria. Br J Clin Pharmacol 1991; 32: 311315.
  • 15
    Pacifici GM, Viani A, Taddeucci-Brunelli G, Rizzo G, Carrai M, Schulz HU. Effects of development, aging, and renal and hepatic insufficiency as well as hemodialysis on the plasma concentrations of albumin and α1-acid glycoprotein: implications for binding of drugs. Ther Drug Monit 1986; 8: 259263.
  • 16
    Gibson TP. Problems in designing hemodialysis drug studies. Pharmacotherapy 1985; 5: 2329.
  • 17
    Bannon P, Yu P, Cook J, Roy LF, Villeneuve JP. The biotransformation of orally administered quinine in man. J Chromatogr B 1998; 715: 387393.
  • 18
    Kremer JMH, Wilting J, Janssen LHM. Drug binding to human alpha-1-acid glycoprotein in health and disease. Pharmacol Rev 1988; 40: 147.
  • 19
    Aronoff GR, Abel SR. Principles of administering drugs to patients with renal failure. Contemporary Issues Nephrol 1987; 17: 119.
  • 20
    Reed WE, Sabatini S. The use of drugs in renal failure. Seminars Nephrol 1986; 6: 259295.
  • 21
    Gulyassy PF, Depner TA. Impaired binding of drugs and endogenous ligands in renal diseases. Am J Kidney Dis 1983; 2: 578601.
  • 22
    Grossman SH, Davis D, Kitchell BB, Shand DG, Routledge PA. Diazepam and lidocaine plasma protein binding in renal disease. Clin Pharmacol Ther 1982; 31: 350357.
  • 23
    Reidenberg MM. The biotransformation of drugs in renal failure. Am J Med 1977; 62: 482485.
  • 24
    Guengerich FP. Human cytochrome P450 enzymes. In Cytochrome P450, ed. Ortiz de Mortellano PR. New York: Plenum Press, 1995: 473535.
  • 25
    Leber HW, Gleumes L, Schufferle G. Enzyme induction in the uremic liver. Kidney Int 1978; 13(Suppl 8): S43S48.